SIMILAR PATTERNS OF AMINO ACIDS FOR 3OG7_A_032A1_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 10 VAL A 18 ALA A 31 LYS A 33 CYH A 83 GLY A 146	None	1.14A	3og7A-1h4lA: 17.7	3og7A-1h4lA: 23.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 10 VAL A 18 ALA A 31 LYS A 33 LEU A 55 CYH A 83	None	0.88A	3og7A-1h4lA: 17.7	3og7A-1h4lA: 23.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 10 VAL A 18 LYS A 33 LEU A 55 CYH A 83 PHE A 145	None	1.07A	3og7A-1h4lA: 17.7	3og7A-1h4lA: 23.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 416 ALA A 428 LYS A 430 THR A 474 PHE A 540 GLY A 541	None	0.87A	3og7A-1k2pA: 22.7	3og7A-1k2pA: 29.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ILE A 201 VAL A 209 ALA A 220 LYS A 222 THR A 266 GLY A 334	None	0.92A	3og7A-1k9aA: 28.0	3og7A-1k9aA: 22.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1q8y	SR PROTEIN KINASE (Saccharomyces cerevisiae)	PF00069 (Pkinase)	5	VAL A 172 ALA A 185 LYS A 187 LEU A 206 LEU A 226	ADP A 810 (-4.1A) ADP A 810 (-3.3A) ADP A 810 (-3.1A) None ADP A 810 (-4.4A)	0.63A	3og7A-1q8yA: 21.0	3og7A-1q8yA: 23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ILE A 369 VAL A 377 ALA A 389 LYS A 391 PHE A 501	None	0.58A	3og7A-1snxA: 29.3	3og7A-1snxA: 29.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 603 ALA A 621 LYS A 623 LEU A 644 THR A 670	STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.7A) STI A 3 (-4.4A) STI A 3 (-3.2A)	0.74A	3og7A-1t46A: 26.9	3og7A-1t46A: 30.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 603 ALA A 621 LYS A 623 THR A 670 CYH A 673	STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.7A) STI A 3 (-3.2A) STI A 3 (-4.5A)	0.35A	3og7A-1t46A: 26.9	3og7A-1t46A: 30.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	ILE A 34 VAL A 42 ALA A 55 LYS A 57 CYH A 108 GLY A 171	None	1.20A	3og7A-1u5qA: 24.5	3og7A-1u5qA: 30.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	ILE A 34 VAL A 42 ALA A 55 LYS A 57 CYH A 108 PHE A 170	None	1.06A	3og7A-1u5qA: 24.5	3og7A-1u5qA: 30.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	VAL A 42 ALA A 55 LYS A 57 LEU A 80 CYH A 108 PHE A 170	None	0.99A	3og7A-1u5qA: 24.5	3og7A-1u5qA: 30.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 23 ALA A 36 LYS A 38 CYH A 87 PHE A 149	HYM A 400 (-4.3A) HYM A 400 (-3.5A) HYM A 400 (-3.2A) HYM A 400 (-4.2A) None	0.74A	3og7A-1zltA: 22.0	3og7A-1zltA: 25.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zy4	SERINE/THREONINE-PRO TEIN KINASE GCN2 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	VAL A 613 ALA A 626 CYH A 791 PHE A 842 PHE A 854 GLY A 855	None GOL A 998 ( 3.7A) GOL A 998 (-4.3A) GOL A 998 ( 4.2A) None None	1.49A	3og7A-1zy4A: 21.9	3og7A-1zy4A: 28.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zy4	SERINE/THREONINE-PRO TEIN KINASE GCN2 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	VAL A 613 ALA A 626 LEU A 647 CYH A 791 PHE A 842 PHE A 854	None GOL A 998 ( 3.7A) None GOL A 998 (-4.3A) GOL A 998 ( 4.2A) None	1.13A	3og7A-1zy4A: 21.9	3og7A-1zy4A: 28.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	ILE B 273 VAL B 281 LYS B 296 CYH B 369 PHE B 421 GLY B 434	None	1.06A	3og7A-2a1aB: 22.4	3og7A-2a1aB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	ILE B 273 VAL B 281 LYS B 296 CYH B 369 PHE B 421 PHE B 433	None	0.96A	3og7A-2a1aB: 22.4	3og7A-2a1aB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2a1a	INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	ILE B 273 VAL B 281 LYS B 296 LEU B 312 PHE B 421 PHE B 433	None	1.22A	3og7A-2a1aB: 22.4	3og7A-2a1aB: 30.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hen	EPHRIN TYPE-B RECEPTOR 2 (Mus musculus)	PF07714 (Pkinase_Tyr)	6	ILE A 635 VAL A 643 ALA A 659 LYS A 661 THR A 707 PHE A 773	ADP A 400 (-4.9A) ADP A 400 ( 4.4A) ADP A 400 (-3.2A) ADP A 400 (-2.7A) ADP A 400 (-4.7A) None	1.11A	3og7A-2henA: 27.8	3og7A-2henA: 31.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 259 ALA A 271 LYS A 273 THR A 316 PHE A 383	1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.8A) 1BM A 499 (-3.2A) None	0.65A	3og7A-2hk5A: 27.0	3og7A-2hk5A: 31.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hw6	MAP KINASE-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 63 ALA A 76 LYS A 78 LEU A 98 LEU A 108 PHE A 230	None	1.01A	3og7A-2hw6A: 20.9	3og7A-2hw6A: 26.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	6	ILE A 428 VAL A 436 ALA A 452 LYS A 454 CYH A 502 GLY A 566	4ST A1687 (-4.2A) 4ST A1687 ( 4.8A) 4ST A1687 (-3.3A) 4ST A1687 (-3.4A) 4ST A1687 (-4.1A) None	1.04A	3og7A-2j0jA: 28.7	3og7A-2j0jA: 18.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	6	ILE A 428 VAL A 436 ALA A 452 LYS A 454 CYH A 502 PHE A 565	4ST A1687 (-4.2A) 4ST A1687 ( 4.8A) 4ST A1687 (-3.3A) 4ST A1687 (-3.4A) 4ST A1687 (-4.1A) None	1.01A	3og7A-2j0jA: 28.7	3og7A-2j0jA: 18.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	ILE A 10 VAL A 18 ALA A 31 LYS A 33 LEU A 55 PHE A 146	None	1.18A	3og7A-2jgzA: 9.7	3og7A-2jgzA: 25.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jkm	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	ILE A 428 VAL A 436 ALA A 452 LYS A 454 CYH A 502 GLY A 566	BII A1687 (-3.8A) BII A1687 ( 4.7A) BII A1687 (-3.5A) BII A1687 (-2.9A) BII A1687 (-4.1A) None	0.82A	3og7A-2jkmA: 28.4	3og7A-2jkmA: 29.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jkm	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	ILE A 428 VAL A 436 ALA A 452 LYS A 454 CYH A 502 PHE A 565	BII A1687 (-3.8A) BII A1687 ( 4.7A) BII A1687 (-3.5A) BII A1687 (-2.9A) BII A1687 (-4.1A) None	1.07A	3og7A-2jkmA: 28.4	3og7A-2jkmA: 29.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 596 ALA A 614 LYS A 616 THR A 663 CYH A 666	None	0.60A	3og7A-2ogvA: 25.2	3og7A-2ogvA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	6	ILE B 47 VAL B 55 ALA B 67 LYS B 69 LEU B 89 PHE B 183	None	1.23A	3og7A-2qkwB: 24.3	3og7A-2qkwB: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 204 ALA A 215 LYS A 217 LEU A 245 THR A 265 GLY A 341	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) None ADE A 488 ( 4.5A) ADE A 488 (-4.3A) None	0.83A	3og7A-2qluA: 25.1	3og7A-2qluA: 26.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 204 ALA A 215 LYS A 217 LEU A 245 THR A 265 PHE A 340	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) None ADE A 488 ( 4.5A) ADE A 488 (-4.3A) None	0.85A	3og7A-2qluA: 25.1	3og7A-2qluA: 26.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 732 ALA A 749 LYS A 751 THR A 796 PHE A 862	GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 (-4.0A) GW7 A 1 (-3.8A)	0.73A	3og7A-2r4bA: 20.8	3og7A-2r4bA: 33.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z2w	WEE1-LIKE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	5	ILE A 305 VAL A 313 CYH A 379 PHE A 433 GLY A 465	770 A 901 (-3.8A) 770 A 901 ( 4.7A) 770 A 901 (-3.9A) 770 A 901 (-4.0A) None	0.73A	3og7A-2z2wA: 23.4	3og7A-2z2wA: 28.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z2w	WEE1-LIKE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 313 ALA A 326 CYH A 379 PHE A 433 GLY A 465	770 A 901 ( 4.7A) 770 A 901 (-3.5A) 770 A 901 (-3.9A) 770 A 901 (-4.0A) None	0.78A	3og7A-2z2wA: 23.4	3og7A-2z2wA: 28.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	5	VAL A 261 ALA A 273 LYS A 275 THR A 319 PHE A 386	None	0.71A	3og7A-2zv7A: 27.6	3og7A-2zv7A: 34.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ILE A 201 VAL A 209 ALA A 220 LYS A 222 THR A 266 GLY A 334	None	0.93A	3og7A-3d7uA: 23.1	3og7A-3d7uA: 30.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3f3z	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase)	6	ILE A 34 VAL A 42 ALA A 55 LYS A 57 CYH A 105 PHE A 170	DRK A 1 (-4.2A) DRK A 1 ( 4.9A) DRK A 1 (-3.4A) DRK A 1 (-4.1A) DRK A 1 (-4.1A) None	1.02A	3og7A-3f3zA: 18.2	3og7A-3f3zA: 25.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 841 ALA A 859 LYS A 861 LEU A 882 CYH A 912	8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-4.0A) None 8ST A2001 (-3.8A)	0.68A	3og7A-3hngA: 26.6	3og7A-3hngA: 27.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	5	VAL A 649 ALA A 665 LYS A 667 THR A 713 PHE A 779	None	0.79A	3og7A-3kulA: 28.5	3og7A-3kulA: 32.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lj0	SERINE/THREONINE-PRO TEIN KINASE/ENDORIBONUCLE ASE IRE1 (Saccharomyces cerevisiae)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A)	5	VAL A 689 ALA A 700 LYS A 702 CYH A 748 PHE A 829	ADP A2101 (-4.5A) ADP A2101 (-3.5A) ADP A2101 (-2.7A) ADP A2101 (-4.2A) None	0.77A	3og7A-3lj0A: 18.3	3og7A-3lj0A: 24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	5	VAL A 218 ALA A 229 LYS A 231 LEU A 259 THR A 279	LDN A 1 ( 4.8A) LDN A 1 (-3.6A) None None LDN A 1 (-3.8A)	0.53A	3og7A-3mdyA: 24.8	3og7A-3mdyA: 29.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 33 ALA A 46 LYS A 48 LEU A 70 CYH A 106 PHE A 168	None	1.05A	3og7A-3mi9A: 16.8	3og7A-3mi9A: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 216 ALA A 227 LYS A 229 LEU A 257 THR A 277	LDN A 600 (-4.5A) LDN A 600 (-3.2A) LDN A 600 (-4.0A) None LDN A 600 (-4.0A)	0.34A	3og7A-3my0A: 25.0	3og7A-3my0A: 26.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	ILE A 355 VAL A 363 ALA A 373 LEU A 397 LEU A 406 THR A 421 TRP A 423 CYH A 424 PHE A 475 PHE A 487	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None	0.79A	3og7A-3omvA: 34.5	3og7A-3omvA: 72.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	ILE A 355 VAL A 363 ALA A 373 LYS A 375 LEU A 397 LEU A 406 THR A 421 TRP A 423 PHE A 475 PHE A 487	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None	0.81A	3og7A-3omvA: 34.5	3og7A-3omvA: 72.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ILE A 355 VAL A 363 ALA A 373 LYS A 375 TRP A 423 PHE A 475 GLY A 488	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None	1.05A	3og7A-3omvA: 34.5	3og7A-3omvA: 72.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ILE A 355 VAL A 363 ALA A 373 TRP A 423 CYH A 424 PHE A 475 GLY A 488	SM5 A 1 (-4.3A) SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) SM5 A 1 (-4.3A) SM5 A 1 ( 4.4A) SM5 A 1 (-3.0A) None	0.97A	3og7A-3omvA: 34.5	3og7A-3omvA: 72.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	5	VAL A 565 ALA A 576 LYS A 578 THR A 625 PHE A 695	STU A 1 (-4.9A) STU A 1 (-3.3A) STU A 1 (-3.5A) STU A 1 (-4.1A) None	0.77A	3og7A-3ppzA: 29.7	3og7A-3ppzA: 38.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 206 ALA A 217 LYS A 219 LEU A 247 THR A 267 PHE A 341	TAK A 2 ( 4.9A) TAK A 2 (-3.5A) TAK A 2 (-2.9A) None TAK A 2 (-3.5A) None	0.82A	3og7A-3q4tA: 25.1	3og7A-3q4tA: 30.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	VAL A 71 ALA A 84 LYS A 86 LEU A 119 THR A 144 PHE A 212	ANP A1634 (-4.1A) ANP A1634 (-3.6A) ANP A1634 (-3.1A) None ANP A1634 (-4.6A) None	0.90A	3og7A-3q5iA: 21.6	3og7A-3q5iA: 21.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q60	ROP5B (Toxoplasma gondii)	PF14531 (Kinase-like)	5	VAL A 248 ALA A 261 LYS A 263 LEU A 304 PHE A 396	ATP A 600 (-4.3A) ATP A 600 (-3.6A) MLI A 601 ( 2.8A) ATP A 600 ( 4.8A) ATP A 600 (-4.4A)	0.61A	3og7A-3q60A: 18.6	3og7A-3q60A: 22.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	VAL B 603 ALA B 616 LYS B 618 CYH B 889 PHE B 942 GLY B 955	None	0.90A	3og7A-3qd2B: 22.3	3og7A-3qd2B: 26.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	VAL B 603 ALA B 616 LYS B 618 CYH B 889 PHE B 942 PHE B 954	None	0.77A	3og7A-3qd2B: 22.3	3og7A-3qd2B: 26.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	VAL B 603 ALA B 616 LYS B 618 LEU B 639 PHE B 942 PHE B 954	None	0.89A	3og7A-3qd2B: 22.3	3og7A-3qd2B: 26.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ILE A 625 VAL A 633 ALA A 649 LYS A 651 THR A 697 PHE A 763	None	0.97A	3og7A-3zfxA: 28.3	3og7A-3zfxA: 32.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4a4l	SERINE/THREONINE-PRO TEIN KINASE PLK1 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 80 LYS A 82 CYH A 133 PHE A 183 PHE A 195	939 A1331 (-3.5A) 939 A1331 (-2.6A) 939 A1331 (-4.0A) 939 A1331 (-4.0A) None	0.72A	3og7A-4a4lA: 18.3	3og7A-4a4lA: 26.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 18 ALA A 31 LYS A 33 LEU A 55 CYH A 83	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None D15 A 500 (-4.3A)	0.76A	3og7A-4aguA: 24.5	3og7A-4aguA: 24.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ILE A 97 VAL A 105 ALA A 121 LYS A 123 THR A 169 PHE A 235	30K A1365 (-4.5A) 30K A1365 ( 4.6A) 30K A1365 (-3.2A) 30K A1365 (-3.8A) 30K A1365 (-3.8A) None	1.01A	3og7A-4aw5A: 28.2	3og7A-4aw5A: 32.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	5	VAL A 222 ALA A 233 LYS A 235 LEU A 263 GLY A 356	TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 ( 4.5A) FLC A1503 ( 4.5A) None	0.73A	3og7A-4c02A: 25.0	3og7A-4c02A: 28.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	5	VAL A 222 ALA A 233 LYS A 235 LEU A 263 THR A 283	TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 ( 4.5A) FLC A1503 ( 4.5A) TAK A1507 (-3.6A)	0.32A	3og7A-4c02A: 25.0	3og7A-4c02A: 28.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	5	VAL A 254 ALA A 267 LYS A 269 LEU A 292 PHE A 383	None	0.72A	3og7A-4c0tA: 22.4	3og7A-4c0tA: 15.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	ILE A 567 VAL A 575 ALA A 588 LYS A 590 LEU A 611 PHE A 702	GUI A 901 (-4.0A) GUI A 901 (-4.5A) GUI A 901 (-3.4A) GUI A 901 (-2.8A) None None	1.29A	3og7A-4e93A: 29.1	3og7A-4e93A: 27.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4euu	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 23 ALA A 36 LYS A 38 LEU A 59 CYH A 89	BX7 A 401 ( 4.6A) BX7 A 401 (-3.4A) BX7 A 401 (-3.5A) None BX7 A 401 (-4.1A)	0.77A	3og7A-4euuA: 17.2	3og7A-4euuA: 26.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 606 ALA A 619 CYH A 890 PHE A 943 PHE A 955 GLY A 956	924 A1101 ( 4.8A) 924 A1101 (-3.5A) 924 A1101 (-3.9A) 924 A1101 ( 4.2A) 924 A1101 ( 4.4A) None	0.84A	3og7A-4g34A: 23.6	3og7A-4g34A: 27.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 606 ALA A 619 LYS A 621 CYH A 890 PHE A 955 GLY A 956	924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 (-3.9A) 924 A1101 ( 4.4A) None	0.79A	3og7A-4g34A: 23.6	3og7A-4g34A: 27.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 606 LYS A 621 LEU A 642 CYH A 890 PHE A 955 GLY A 956	924 A1101 ( 4.8A) None 924 A1101 (-3.9A) 924 A1101 (-3.9A) 924 A1101 ( 4.4A) None	0.75A	3og7A-4g34A: 23.6	3og7A-4g34A: 27.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4j7b	POLO-LIKE KINASE (Danio rerio)	PF00069 (Pkinase)	5	ALA A 66 LYS A 68 CYH A 119 PHE A 169 PHE A 181	None	0.79A	3og7A-4j7bA: 24.2	3og7A-4j7bA: 27.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jlc	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Mus musculus)	PF00069 (Pkinase)	6	VAL A 23 ALA A 36 LYS A 38 CYH A 89 PHE A 158 GLY A 159	None SU6 A 701 (-3.4A) None SU6 A 701 (-3.8A) None None	0.71A	3og7A-4jlcA: 20.9	3og7A-4jlcA: 18.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jxf	SERINE/THREONINE-PRO TEIN KINASE PLK4 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 26 ALA A 39 LYS A 41 LEU A 73 CYH A 92 PHE A 155	631 A 301 (-4.6A) 631 A 301 (-3.3A) 631 A 301 (-2.7A) None 631 A 301 (-4.5A) None	0.86A	3og7A-4jxfA: 19.5	3og7A-4jxfA: 26.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	VAL A 36 ALA A 49 LYS A 51 LEU A 74 THR A 95 PHE A 162	ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) None ANP A 401 (-3.8A) None	0.73A	3og7A-4m69A: 27.2	3og7A-4m69A: 27.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 54 ALA A 67 LYS A 69 THR A 123 CYH A 126 PHE A 192	None SIN A 401 ( 3.7A) None None SIN A 401 (-4.3A) None	0.67A	3og7A-4o38A: 20.9	3og7A-4o38A: 26.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tyh	MITOGEN-ACTIVATED PROTEIN KINASE 14 (Mus musculus)	PF00069 (Pkinase)	5	VAL B 38 ALA B 51 LYS B 53 LEU B 75 THR B 106	None 39G B 401 (-3.5A) 39G B 401 (-4.2A) 39G B 401 (-4.3A) 39G B 401 (-3.6A)	0.70A	3og7A-4tyhB: 19.2	3og7A-4tyhB: 25.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	5	VAL A 22 ALA A 35 LYS A 37 THR A 81 PHE A 148	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-4.5A) None	0.71A	3og7A-4ueuA: 27.9	3og7A-4ueuA: 35.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	5	VAL A 416 ALA A 428 LYS A 430 THR A 474 PHE A 540	746 A 702 ( 4.3A) 746 A 702 (-2.4A) 746 A 702 (-3.7A) 746 A 702 (-3.7A) None	0.69A	3og7A-4y93A: 28.9	3og7A-4y93A: 21.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ysj	CALMODULIN-LIKE DOMAIN PROTEIN KINASE (Eimeria tenella)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	VAL A 42 ALA A 55 LYS A 57 LEU A 80 THR A 105 PHE A 173	ADP A 506 (-4.3A) ADP A 506 (-3.3A) ADP A 506 (-2.4A) None ADP A 506 ( 4.6A) None	0.97A	3og7A-4ysjA: 25.5	3og7A-4ysjA: 22.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 492 ALA A 512 LYS A 514 PHE A 642 GLY A 643	38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 ( 3.1A) EDO A1766 (-3.7A) EDO A1766 (-3.6A)	0.70A	3og7A-5a46A: 27.0	3og7A-5a46A: 27.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5d7a	TRAF2 AND NCK-INTERACTING PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 39 ALA A 52 LYS A 54 LEU A 73 PHE A 172	VAL A 39 (-0.6A) ALA A 52 (-0.0A) LYS A 54 ( 0.0A) LEU A 73 ( 0.6A) PHE A 172 ( 1.3A)	0.67A	3og7A-5d7aA: 25.5	3og7A-5d7aA: 29.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 258 ALA A 275 LYS A 277 LEU A 305 THR A 325 PHE A 398	STU A 601 (-4.0A) STU A 601 (-3.1A) STU A 601 (-2.4A) STU A 601 ( 3.8A) STU A 601 ( 3.7A) None	0.81A	3og7A-5e8yA: 25.0	3og7A-5e8yA: 27.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fd2	SERINE/THREONINE-PRO TEIN KINASE B-RAF (Homo sapiens)	PF07714 (Pkinase_Tyr)	12	ILE A 463 VAL A 471 ALA A 481 LYS A 483 LEU A 505 LEU A 514 THR A 529 TRP A 531 CYH A 532 PHE A 583 PHE A 595 GLY A 596	5XJ A 801 ( 4.7A) 5XJ A 801 (-4.6A) 5XJ A 801 (-3.1A) 5XJ A 801 (-3.8A) 5XJ A 801 (-3.8A) 5XJ A 801 (-4.5A) 5XJ A 801 (-3.4A) 5XJ A 801 (-4.4A) 5XJ A 801 (-4.6A) 5XJ A 801 (-4.3A) 5XJ A 801 (-3.7A) 5XJ A 801 (-3.7A)	0.57A	3og7A-5fd2A: 37.3	3og7A-5fd2A: 90.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 607 ALA A 625 LYS A 627 THR A 674 CYH A 677	748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 (-3.2A) 748 A1001 (-4.5A)	0.38A	3og7A-5grnA: 26.9	3og7A-5grnA: 28.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hes	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 30 ALA A 43 LYS A 45 LEU A 57 THR A 82 PHE A 152 GLY A 153	032 A 401 (-4.4A) 032 A 401 (-3.2A) 032 A 401 (-4.4A) 032 A 401 ( 4.7A) 032 A 401 (-3.7A) 032 A 401 (-4.1A) 032 A 401 (-3.6A)	0.60A	3og7A-5hesA: 26.8	3og7A-5hesA: 31.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hor	HEPATOCYTE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A1092 ALA A1108 LEU A1140 PHE A1223 GLY A1224	63K A1401 (-4.9A) 63K A1401 (-3.5A) None None None	0.54A	3og7A-5horA: 26.0	3og7A-5horA: 29.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 30 ALA A 43 LYS A 45 CYH A 93 PHE A 155	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) 6G2 A 901 ( 3.9A) TPO A 145 (-4.1A) None	0.74A	3og7A-5j5tA: 22.1	3og7A-5j5tA: 25.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5kkr	KINASE SUPPRESSOR OF RAS 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ILE B 672 VAL B 680 ALA B 690 THR B 739 CYH B 742 PHE B 804	6U7 B1001 ( 4.8A) 6U7 B1001 ( 4.3A) 6U7 B1001 (-3.6A) 6U7 B1001 (-4.0A) 6U7 B1001 (-3.5A) 6U7 B1001 (-3.8A)	1.01A	3og7A-5kkrB: 17.0	3og7A-5kkrB: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5kkr	KINASE SUPPRESSOR OF RAS 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ILE B 672 VAL B 680 ALA B 690 THR B 739 PHE B 793	6U7 B1001 ( 4.8A) 6U7 B1001 ( 4.3A) 6U7 B1001 (-3.6A) 6U7 B1001 (-4.0A) 6U7 B1001 (-4.3A)	0.71A	3og7A-5kkrB: 17.0	3og7A-5kkrB: 36.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ko1	MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ALA A 228 LYS A 230 LEU A 263 CYH A 286 PHE A 350	6UY A 501 (-3.4A) 6UY A 501 (-4.0A) None 6UY A 501 (-4.3A) None	0.79A	3og7A-5ko1A: 26.1	3og7A-5ko1A: 26.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5l6o	EPHRIN TYPE-B RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	ILE A 639 VAL A 647 ALA A 663 LYS A 665 THR A 711	6P6 A1001 (-4.0A) None 6P6 A1001 (-3.3A) None 6P6 A1001 (-3.5A)	0.74A	3og7A-5l6oA: 26.8	3og7A-5l6oA: 30.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5o2c	SERINE/THREONINE-PRO TEIN KINASE WNK3 (Homo sapiens)	PF00069 (Pkinase) PF12202 (OSR1_C)	5	VAL A 161 ALA A 174 LEU A 198 THR A 227 PHE A 282	None GOL A 604 ( 3.8A) None GOL A 604 (-3.9A) GOL A 604 ( 4.5A)	0.73A	3og7A-5o2cA: 26.3	3og7A-5o2cA: 26.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tvt	MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (Homo sapiens)	no annotation	5	VAL A 25 ALA A 38 LYS A 40 CYH A 89 PHE A 151	7LV A 401 ( 4.6A) 7LV A 401 (-3.4A) 7LV A 401 (-3.0A) 7LV A 401 (-4.3A) None	0.79A	3og7A-5tvtA: 23.3	3og7A-5tvtA: 26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 124 ALA A 137 LYS A 139 THR A 187 CYH A 190 GLY A 253	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-4.9A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None	1.13A	3og7A-5vcxA: 18.1	3og7A-5vcxA: 25.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 124 ALA A 137 THR A 187 CYH A 190 PHE A 240 GLY A 253	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 (-4.3A) None	0.67A	3og7A-5vcxA: 18.1	3og7A-5vcxA: 25.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 124 ALA A 137 THR A 187 CYH A 190 PHE A 240 PHE A 252	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) H8H A 401 (-4.3A) None	0.83A	3og7A-5vcxA: 18.1	3og7A-5vcxA: 25.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vdk	WEE1-LIKE PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	ILE A 218 VAL A 226 CYH A 292 PHE A 346 GLY A 382	8X7 A 501 ( 4.0A) 8X7 A 501 ( 4.5A) 8X7 A 501 (-3.8A) 8X7 A 501 (-3.7A) None	0.78A	3og7A-5vdkA: 22.7	3og7A-5vdkA: 28.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vo1	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 12 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 139 ALA A 150 LYS A 152 CYH A 193 PHE A 255	9FS A 501 (-4.5A) 9FS A 501 (-3.4A) None 9FS A 501 (-4.3A) None	0.74A	3og7A-5vo1A: 27.3	3og7A-5vo1A: 37.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	5	VAL A 32 ALA A 45 LYS A 47 LEU A 79 THR A 95	9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) 9WS A 401 (-3.3A) 9WS A 401 (-4.9A) 9WS A 401 (-3.2A)	0.57A	3og7A-5w5jA: 26.7	3og7A-5w5jA: 29.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	5	VAL A 899 ALA A 917 LEU A 947 THR A 963 PHE A1029	ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-4.7A) ANP A1201 (-3.9A) None	0.54A	3og7A-5wnoA: 27.3	3og7A-5wnoA: 11.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5x1t	PPKA-294 (Serratia sp. FS14)	no annotation	6	ILE A 29 VAL A 37 ALA A 50 LYS A 52 LEU A 93 THR A 118	None ADP A 401 ( 4.5A) ADP A 401 (-3.4A) None None ADP A 401 (-4.1A)	1.04A	3og7A-5x1tA: 21.8	3og7A-5x1tA: 14.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	5	VAL A 41 ALA A 54 CYH A 102 PHE A 165 GLY A 166	ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-4.2A) None None	0.69A	3og7A-6ao5A: 24.5	3og7A-6ao5A: 24.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b4w	DUAL SPECIFICITY PROTEIN KINASE TTK (Homo sapiens)	no annotation	5	ILE A 531 VAL A 539 ALA A 551 LYS A 553 PHE A 665	CQ7 A 801 (-3.6A) CQ7 A 801 ( 4.8A) CQ7 A 801 (-3.2A) CQ7 A 801 (-3.2A) None	0.74A	3og7A-6b4wA: 23.9	3og7A-6b4wA: 28.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	no annotation	6	ILE A 218 VAL A 226 ALA A 237 LYS A 239 LEU A 263 PHE A 359	DL1 A 601 (-4.0A) None DL1 A 601 (-3.4A) DL1 A 601 ( 4.1A) None None	1.27A	3og7A-6bfnA: 24.6	3og7A-6bfnA: 13.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cmj	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	6	ILE A 171 VAL A 179 ALA A 192 LYS A 194 LEU A 240 PHE A 331	F6J A 501 (-4.3A) F6J A 501 (-4.6A) F6J A 501 (-3.4A) F6J A 501 (-2.9A) None None	1.18A	3og7A-6cmjA: 17.9	3og7A-6cmjA: 16.49

[["3OG7_A_032A1_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",6,"ILE A  10;VAL A  18;ALA A  31;LYS A  33;CYH A  83;GLY A 146","None","1.14A","3og7A-1h4lA:17.7","3og7A-1h4lA:23.32"],["3OG7_A_032A1_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",6,"ILE A  10;VAL A  18;ALA A  31;LYS A  33;LEU A  55;CYH A  83","None","0.88A","3og7A-1h4lA:17.7","3og7A-1h4lA:23.32"],["3OG7_A_032A1_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",6,"ILE A  10;VAL A  18;LYS A  33;LEU A  55;CYH A  83;PHE A 145","None","1.07A","3og7A-1h4lA:17.7","3og7A-1h4lA:23.32"],["3OG7_A_032A1_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",6,"VAL A 416;ALA A 428;LYS A 430;THR A 474;PHE A 540;GLY A 541","None","0.87A","3og7A-1k2pA:22.7","3og7A-1k2pA:29.22"],["3OG7_A_032A1_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ILE A 201;VAL A 209;ALA A 220;LYS A 222;THR A 266;GLY A 334","None","0.92A","3og7A-1k9aA:28.0","3og7A-1k9aA:22.32"],["3OG7_A_032A1_1","1q8y","Saccharomyces cerevisiae","SR PROTEIN KINASE","PF00069(Pkinase)",5,"VAL A 172;ALA A 185;LYS A 187;LEU A 206;LEU A 226","ADP A 810 (-4.1A);ADP A 810 (-3.3A);ADP A 810 (-3.1A);None;ADP A 810 (-4.4A)","0.63A","3og7A-1q8yA:21.0","3og7A-1q8yA:23.38"],["3OG7_A_032A1_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",5,"ILE A 369;VAL A 377;ALA A 389;LYS A 391;PHE A 501","None","0.58A","3og7A-1snxA:29.3","3og7A-1snxA:29.10"],["3OG7_A_032A1_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",5,"VAL A 603;ALA A 621;LYS A 623;LEU A 644;THR A 670","STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.7A);STI A   3 (-4.4A);STI A   3 (-3.2A)","0.74A","3og7A-1t46A:26.9","3og7A-1t46A:30.41"],["3OG7_A_032A1_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",5,"VAL A 603;ALA A 621;LYS A 623;THR A 670;CYH A 673","STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.7A);STI A   3 (-3.2A);STI A   3 (-4.5A)","0.35A","3og7A-1t46A:26.9","3og7A-1t46A:30.41"],["3OG7_A_032A1_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"ILE A  34;VAL A  42;ALA A  55;LYS A  57;CYH A 108;GLY A 171","None","1.20A","3og7A-1u5qA:24.5","3og7A-1u5qA:30.00"],["3OG7_A_032A1_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"ILE A  34;VAL A  42;ALA A  55;LYS A  57;CYH A 108;PHE A 170","None","1.06A","3og7A-1u5qA:24.5","3og7A-1u5qA:30.00"],["3OG7_A_032A1_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"VAL A  42;ALA A  55;LYS A  57;LEU A  80;CYH A 108;PHE A 170","None","0.99A","3og7A-1u5qA:24.5","3og7A-1u5qA:30.00"],["3OG7_A_032A1_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",5,"VAL A  23;ALA A  36;LYS A  38;CYH A  87;PHE A 149","HYM A 400 (-4.3A);HYM A 400 (-3.5A);HYM A 400 (-3.2A);HYM A 400 (-4.2A);None","0.74A","3og7A-1zltA:22.0","3og7A-1zltA:25.31"],["3OG7_A_032A1_1","1zy4","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE GCN2","PF00069(Pkinase)",6,"VAL A 613;ALA A 626;CYH A 791;PHE A 842;PHE A 854;GLY A 855","None;GOL A 998 ( 3.7A);GOL A 998 (-4.3A);GOL A 998 ( 4.2A);None;None","1.49A","3og7A-1zy4A:21.9","3og7A-1zy4A:28.18"],["3OG7_A_032A1_1","1zy4","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE GCN2","PF00069(Pkinase)",6,"VAL A 613;ALA A 626;LEU A 647;CYH A 791;PHE A 842;PHE A 854","None;GOL A 998 ( 3.7A);None;GOL A 998 (-4.3A);GOL A 998 ( 4.2A);None","1.13A","3og7A-1zy4A:21.9","3og7A-1zy4A:28.18"],["3OG7_A_032A1_1","2a1a","Homo sapiens","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","PF00069(Pkinase)",6,"ILE B 273;VAL B 281;LYS B 296;CYH B 369;PHE B 421;GLY B 434","None","1.06A","3og7A-2a1aB:22.4","3og7A-2a1aB:30.88"],["3OG7_A_032A1_1","2a1a","Homo sapiens","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","PF00069(Pkinase)",6,"ILE B 273;VAL B 281;LYS B 296;CYH B 369;PHE B 421;PHE B 433","None","0.96A","3og7A-2a1aB:22.4","3og7A-2a1aB:30.88"],["3OG7_A_032A1_1","2a1a","Homo sapiens","INTERFERON-INDUCED, DOUBLE-STRANDED RNA-ACTIVATED PROTEIN KINASE","PF00069(Pkinase)",6,"ILE B 273;VAL B 281;LYS B 296;LEU B 312;PHE B 421;PHE B 433","None","1.22A","3og7A-2a1aB:22.4","3og7A-2a1aB:30.88"],["3OG7_A_032A1_1","2hen","Mus musculus","EPHRIN TYPE-B RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"ILE A 635;VAL A 643;ALA A 659;LYS A 661;THR A 707;PHE A 773","ADP A 400 (-4.9A);ADP A 400 ( 4.4A);ADP A 400 (-3.2A);ADP A 400 (-2.7A);ADP A 400 (-4.7A);None","1.11A","3og7A-2henA:27.8","3og7A-2henA:31.27"],["3OG7_A_032A1_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",5,"VAL A 259;ALA A 271;LYS A 273;THR A 316;PHE A 383","1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.8A);1BM A 499 (-3.2A);None","0.65A","3og7A-2hk5A:27.0","3og7A-2hk5A:31.19"],["3OG7_A_032A1_1","2hw6","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 1","PF00069(Pkinase)",6,"VAL A  63;ALA A  76;LYS A  78;LEU A  98;LEU A 108;PHE A 230","None","1.01A","3og7A-2hw6A:20.9","3og7A-2hw6A:26.81"],["3OG7_A_032A1_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",6,"ILE A 428;VAL A 436;ALA A 452;LYS A 454;CYH A 502;GLY A 566","4ST A1687 (-4.2A);4ST A1687 ( 4.8A);4ST A1687 (-3.3A);4ST A1687 (-3.4A);4ST A1687 (-4.1A);None","1.04A","3og7A-2j0jA:28.7","3og7A-2j0jA:18.33"],["3OG7_A_032A1_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",6,"ILE A 428;VAL A 436;ALA A 452;LYS A 454;CYH A 502;PHE A 565","4ST A1687 (-4.2A);4ST A1687 ( 4.8A);4ST A1687 (-3.3A);4ST A1687 (-3.4A);4ST A1687 (-4.1A);None","1.01A","3og7A-2j0jA:28.7","3og7A-2j0jA:18.33"],["3OG7_A_032A1_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",6,"ILE A  10;VAL A  18;ALA A  31;LYS A  33;LEU A  55;PHE A 146","None","1.18A","3og7A-2jgzA:9.7","3og7A-2jgzA:25.25"],["3OG7_A_032A1_1","2jkm","Gallus gallus","FOCAL ADHESION KINASE 1","PF07714(Pkinase_Tyr)",6,"ILE A 428;VAL A 436;ALA A 452;LYS A 454;CYH A 502;GLY A 566","BII A1687 (-3.8A);BII A1687 ( 4.7A);BII A1687 (-3.5A);BII A1687 (-2.9A);BII A1687 (-4.1A);None","0.82A","3og7A-2jkmA:28.4","3og7A-2jkmA:29.22"],["3OG7_A_032A1_1","2jkm","Gallus gallus","FOCAL ADHESION KINASE 1","PF07714(Pkinase_Tyr)",6,"ILE A 428;VAL A 436;ALA A 452;LYS A 454;CYH A 502;PHE A 565","BII A1687 (-3.8A);BII A1687 ( 4.7A);BII A1687 (-3.5A);BII A1687 (-2.9A);BII A1687 (-4.1A);None","1.07A","3og7A-2jkmA:28.4","3og7A-2jkmA:29.22"],["3OG7_A_032A1_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",5,"VAL A 596;ALA A 614;LYS A 616;THR A 663;CYH A 666","None","0.60A","3og7A-2ogvA:25.2","3og7A-2ogvA:28.57"],["3OG7_A_032A1_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"ILE B  47;VAL B  55;ALA B  67;LYS B  69;LEU B  89;PHE B 183","None","1.23A","3og7A-2qkwB:24.3","3og7A-2qkwB:28.53"],["3OG7_A_032A1_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"VAL A 204;ALA A 215;LYS A 217;LEU A 245;THR A 265;GLY A 341","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);None;ADE A 488 ( 4.5A);ADE A 488 (-4.3A);None","0.83A","3og7A-2qluA:25.1","3og7A-2qluA:26.98"],["3OG7_A_032A1_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"VAL A 204;ALA A 215;LYS A 217;LEU A 245;THR A 265;PHE A 340","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);None;ADE A 488 ( 4.5A);ADE A 488 (-4.3A);None","0.85A","3og7A-2qluA:25.1","3og7A-2qluA:26.98"],["3OG7_A_032A1_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",5,"VAL A 732;ALA A 749;LYS A 751;THR A 796;PHE A 862","GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 (-4.0A);GW7 A   1 (-3.8A)","0.73A","3og7A-2r4bA:20.8","3og7A-2r4bA:33.63"],["3OG7_A_032A1_1","2z2w","Homo sapiens","WEE1-LIKE PROTEIN KINASE","PF00069(Pkinase)",5,"ILE A 305;VAL A 313;CYH A 379;PHE A 433;GLY A 465","770 A 901 (-3.8A);770 A 901 ( 4.7A);770 A 901 (-3.9A);770 A 901 (-4.0A);None","0.73A","3og7A-2z2wA:23.4","3og7A-2z2wA:28.09"],["3OG7_A_032A1_1","2z2w","Homo sapiens","WEE1-LIKE PROTEIN KINASE","PF00069(Pkinase)",5,"VAL A 313;ALA A 326;CYH A 379;PHE A 433;GLY A 465","770 A 901 ( 4.7A);770 A 901 (-3.5A);770 A 901 (-3.9A);770 A 901 (-4.0A);None","0.78A","3og7A-2z2wA:23.4","3og7A-2z2wA:28.09"],["3OG7_A_032A1_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",5,"VAL A 261;ALA A 273;LYS A 275;THR A 319;PHE A 386","None","0.71A","3og7A-2zv7A:27.6","3og7A-2zv7A:34.01"],["3OG7_A_032A1_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"ILE A 201;VAL A 209;ALA A 220;LYS A 222;THR A 266;GLY A 334","None","0.93A","3og7A-3d7uA:23.1","3og7A-3d7uA:30.43"],["3OG7_A_032A1_1","3f3z","Cryptosporidium parvum","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS","PF00069(Pkinase)",6,"ILE A  34;VAL A  42;ALA A  55;LYS A  57;CYH A 105;PHE A 170","DRK A   1 (-4.2A);DRK A   1 ( 4.9A);DRK A   1 (-3.4A);DRK A   1 (-4.1A);DRK A   1 (-4.1A);None","1.02A","3og7A-3f3zA:18.2","3og7A-3f3zA:25.72"],["3OG7_A_032A1_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",5,"VAL A 841;ALA A 859;LYS A 861;LEU A 882;CYH A 912","8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-4.0A);None;8ST A2001 (-3.8A)","0.68A","3og7A-3hngA:26.6","3og7A-3hngA:27.01"],["3OG7_A_032A1_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",5,"VAL A 649;ALA A 665;LYS A 667;THR A 713;PHE A 779","None","0.79A","3og7A-3kulA:28.5","3og7A-3kulA:32.54"],["3OG7_A_032A1_1","3lj0","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE\/ENDORIBONUCLEASE IRE1","PF00069(Pkinase);PF06479(Ribonuc_2-5A)",5,"VAL A 689;ALA A 700;LYS A 702;CYH A 748;PHE A 829","ADP A2101 (-4.5A);ADP A2101 (-3.5A);ADP A2101 (-2.7A);ADP A2101 (-4.2A);None","0.77A","3og7A-3lj0A:18.3","3og7A-3lj0A:24.66"],["3OG7_A_032A1_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",5,"VAL A 218;ALA A 229;LYS A 231;LEU A 259;THR A 279","LDN A   1 ( 4.8A);LDN A   1 (-3.6A);None;None;LDN A   1 (-3.8A)","0.53A","3og7A-3mdyA:24.8","3og7A-3mdyA:29.77"],["3OG7_A_032A1_1","3mi9","Homo sapiens","CELL DIVISION PROTEIN KINASE 9","PF00069(Pkinase)",6,"VAL A  33;ALA A  46;LYS A  48;LEU A  70;CYH A 106;PHE A 168","None","1.05A","3og7A-3mi9A:16.8","3og7A-3mi9A:25.00"],["3OG7_A_032A1_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",5,"VAL A 216;ALA A 227;LYS A 229;LEU A 257;THR A 277","LDN A 600 (-4.5A);LDN A 600 (-3.2A);LDN A 600 (-4.0A);None;LDN A 600 (-4.0A)","0.34A","3og7A-3my0A:25.0","3og7A-3my0A:26.95"],["3OG7_A_032A1_1","3omv","Homo sapiens","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",10,"ILE A 355;VAL A 363;ALA A 373;LEU A 397;LEU A 406;THR A 421;TRP A 423;CYH A 424;PHE A 475;PHE A 487","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None","0.79A","3og7A-3omvA:34.5","3og7A-3omvA:72.09"],["3OG7_A_032A1_1","3omv","Homo sapiens","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",10,"ILE A 355;VAL A 363;ALA A 373;LYS A 375;LEU A 397;LEU A 406;THR A 421;TRP A 423;PHE A 475;PHE A 487","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None","0.81A","3og7A-3omvA:34.5","3og7A-3omvA:72.09"],["3OG7_A_032A1_1","3omv","Homo sapiens","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",7,"ILE A 355;VAL A 363;ALA A 373;LYS A 375;TRP A 423;PHE A 475;GLY A 488","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None","1.05A","3og7A-3omvA:34.5","3og7A-3omvA:72.09"],["3OG7_A_032A1_1","3omv","Homo sapiens","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",7,"ILE A 355;VAL A 363;ALA A 373;TRP A 423;CYH A 424;PHE A 475;GLY A 488","SM5 A   1 (-4.3A);SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);SM5 A   1 (-4.3A);SM5 A   1 ( 4.4A);SM5 A   1 (-3.0A);None","0.97A","3og7A-3omvA:34.5","3og7A-3omvA:72.09"],["3OG7_A_032A1_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",5,"VAL A 565;ALA A 576;LYS A 578;THR A 625;PHE A 695","STU A   1 (-4.9A);STU A   1 (-3.3A);STU A   1 (-3.5A);STU A   1 (-4.1A);None","0.77A","3og7A-3ppzA:29.7","3og7A-3ppzA:38.98"],["3OG7_A_032A1_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",6,"VAL A 206;ALA A 217;LYS A 219;LEU A 247;THR A 267;PHE A 341","TAK A   2 ( 4.9A);TAK A   2 (-3.5A);TAK A   2 (-2.9A);None;TAK A   2 (-3.5A);None","0.82A","3og7A-3q4tA:25.1","3og7A-3q4tA:30.95"],["3OG7_A_032A1_1","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",6,"VAL A  71;ALA A  84;LYS A  86;LEU A 119;THR A 144;PHE A 212","ANP A1634 (-4.1A);ANP A1634 (-3.6A);ANP A1634 (-3.1A);None;ANP A1634 (-4.6A);None","0.90A","3og7A-3q5iA:21.6","3og7A-3q5iA:21.34"],["3OG7_A_032A1_1","3q60","Toxoplasma gondii","ROP5B","PF14531(Kinase-like)",5,"VAL A 248;ALA A 261;LYS A 263;LEU A 304;PHE A 396","ATP A 600 (-4.3A);ATP A 600 (-3.6A);MLI A 601 ( 2.8A);ATP A 600 ( 4.8A);ATP A 600 (-4.4A)","0.61A","3og7A-3q60A:18.6","3og7A-3q60A:22.54"],["3OG7_A_032A1_1","3qd2","Mus musculus","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","PF00069(Pkinase)",6,"VAL B 603;ALA B 616;LYS B 618;CYH B 889;PHE B 942;GLY B 955","None","0.90A","3og7A-3qd2B:22.3","3og7A-3qd2B:26.92"],["3OG7_A_032A1_1","3qd2","Mus musculus","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","PF00069(Pkinase)",6,"VAL B 603;ALA B 616;LYS B 618;CYH B 889;PHE B 942;PHE B 954","None","0.77A","3og7A-3qd2B:22.3","3og7A-3qd2B:26.92"],["3OG7_A_032A1_1","3qd2","Mus musculus","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","PF00069(Pkinase)",6,"VAL B 603;ALA B 616;LYS B 618;LEU B 639;PHE B 942;PHE B 954","None","0.89A","3og7A-3qd2B:22.3","3og7A-3qd2B:26.92"],["3OG7_A_032A1_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"ILE A 625;VAL A 633;ALA A 649;LYS A 651;THR A 697;PHE A 763","None","0.97A","3og7A-3zfxA:28.3","3og7A-3zfxA:32.58"],["3OG7_A_032A1_1","4a4l","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK1","PF00069(Pkinase)",5,"ALA A  80;LYS A  82;CYH A 133;PHE A 183;PHE A 195","939 A1331 (-3.5A);939 A1331 (-2.6A);939 A1331 (-4.0A);939 A1331 (-4.0A);None","0.72A","3og7A-4a4lA:18.3","3og7A-4a4lA:26.65"],["3OG7_A_032A1_1","4agu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 1","PF00069(Pkinase)",5,"VAL A  18;ALA A  31;LYS A  33;LEU A  55;CYH A  83","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;D15 A 500 (-4.3A)","0.76A","3og7A-4aguA:24.5","3og7A-4aguA:24.10"],["3OG7_A_032A1_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",6,"ILE A  97;VAL A 105;ALA A 121;LYS A 123;THR A 169;PHE A 235","30K A1365 (-4.5A);30K A1365 ( 4.6A);30K A1365 (-3.2A);30K A1365 (-3.8A);30K A1365 (-3.8A);None","1.01A","3og7A-4aw5A:28.2","3og7A-4aw5A:32.18"],["3OG7_A_032A1_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",5,"VAL A 222;ALA A 233;LYS A 235;LEU A 263;GLY A 356","TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 ( 4.5A);FLC A1503 ( 4.5A);None","0.73A","3og7A-4c02A:25.0","3og7A-4c02A:28.74"],["3OG7_A_032A1_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",5,"VAL A 222;ALA A 233;LYS A 235;LEU A 263;THR A 283","TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 ( 4.5A);FLC A1503 ( 4.5A);TAK A1507 (-3.6A)","0.32A","3og7A-4c02A:25.0","3og7A-4c02A:28.74"],["3OG7_A_032A1_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",5,"VAL A 254;ALA A 267;LYS A 269;LEU A 292;PHE A 383","None","0.72A","3og7A-4c0tA:22.4","3og7A-4c0tA:15.57"],["3OG7_A_032A1_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"ILE A 567;VAL A 575;ALA A 588;LYS A 590;LEU A 611;PHE A 702","GUI A 901 (-4.0A);GUI A 901 (-4.5A);GUI A 901 (-3.4A);GUI A 901 (-2.8A);None;None","1.29A","3og7A-4e93A:29.1","3og7A-4e93A:27.01"],["3OG7_A_032A1_1","4euu","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",5,"VAL A  23;ALA A  36;LYS A  38;LEU A  59;CYH A  89","BX7 A 401 ( 4.6A);BX7 A 401 (-3.4A);BX7 A 401 (-3.5A);None;BX7 A 401 (-4.1A)","0.77A","3og7A-4euuA:17.2","3og7A-4euuA:26.49"],["3OG7_A_032A1_1","4g34","Homo sapiens","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","PF00069(Pkinase)",6,"VAL A 606;ALA A 619;CYH A 890;PHE A 943;PHE A 955;GLY A 956","924 A1101 ( 4.8A);924 A1101 (-3.5A);924 A1101 (-3.9A);924 A1101 ( 4.2A);924 A1101 ( 4.4A);None","0.84A","3og7A-4g34A:23.6","3og7A-4g34A:27.30"],["3OG7_A_032A1_1","4g34","Homo sapiens","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","PF00069(Pkinase)",6,"VAL A 606;ALA A 619;LYS A 621;CYH A 890;PHE A 955;GLY A 956","924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 (-3.9A);924 A1101 ( 4.4A);None","0.79A","3og7A-4g34A:23.6","3og7A-4g34A:27.30"],["3OG7_A_032A1_1","4g34","Homo sapiens","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","PF00069(Pkinase)",6,"VAL A 606;LYS A 621;LEU A 642;CYH A 890;PHE A 955;GLY A 956","924 A1101 ( 4.8A);None;924 A1101 (-3.9A);924 A1101 (-3.9A);924 A1101 ( 4.4A);None","0.75A","3og7A-4g34A:23.6","3og7A-4g34A:27.30"],["3OG7_A_032A1_1","4j7b","Danio rerio","POLO-LIKE KINASE","PF00069(Pkinase)",5,"ALA A  66;LYS A  68;CYH A 119;PHE A 169;PHE A 181","None","0.79A","3og7A-4j7bA:24.2","3og7A-4j7bA:27.53"],["3OG7_A_032A1_1","4jlc","Mus musculus","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",6,"VAL A  23;ALA A  36;LYS A  38;CYH A  89;PHE A 158;GLY A 159","None;SU6 A 701 (-3.4A);None;SU6 A 701 (-3.8A);None;None","0.71A","3og7A-4jlcA:20.9","3og7A-4jlcA:18.02"],["3OG7_A_032A1_1","4jxf","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK4","PF00069(Pkinase)",6,"VAL A  26;ALA A  39;LYS A  41;LEU A  73;CYH A  92;PHE A 155","631 A 301 (-4.6A);631 A 301 (-3.3A);631 A 301 (-2.7A);None;631 A 301 (-4.5A);None","0.86A","3og7A-4jxfA:19.5","3og7A-4jxfA:26.01"],["3OG7_A_032A1_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"VAL A  36;ALA A  49;LYS A  51;LEU A  74;THR A  95;PHE A 162","ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);None;ANP A 401 (-3.8A);None","0.73A","3og7A-4m69A:27.2","3og7A-4m69A:27.58"],["3OG7_A_032A1_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",6,"VAL A  54;ALA A  67;LYS A  69;THR A 123;CYH A 126;PHE A 192","None;SIN A 401 ( 3.7A);None;None;SIN A 401 (-4.3A);None","0.67A","3og7A-4o38A:20.9","3og7A-4o38A:26.24"],["3OG7_A_032A1_1","4tyh","Mus musculus","MITOGEN-ACTIVATED PROTEIN KINASE 14","PF00069(Pkinase)",5,"VAL B  38;ALA B  51;LYS B  53;LEU B  75;THR B 106","None;39G B 401 (-3.5A);39G B 401 (-4.2A);39G B 401 (-4.3A);39G B 401 (-3.6A)","0.70A","3og7A-4tyhB:19.2","3og7A-4tyhB:25.91"],["3OG7_A_032A1_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",5,"VAL A  22;ALA A  35;LYS A  37;THR A  81;PHE A 148","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);None","0.71A","3og7A-4ueuA:27.9","3og7A-4ueuA:35.55"],["3OG7_A_032A1_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",5,"VAL A 416;ALA A 428;LYS A 430;THR A 474;PHE A 540","746 A 702 ( 4.3A);746 A 702 (-2.4A);746 A 702 (-3.7A);746 A 702 (-3.7A);None","0.69A","3og7A-4y93A:28.9","3og7A-4y93A:21.91"],["3OG7_A_032A1_1","4ysj","Eimeria tenella","CALMODULIN-LIKE DOMAIN PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",6,"VAL A  42;ALA A  55;LYS A  57;LEU A  80;THR A 105;PHE A 173","ADP A 506 (-4.3A);ADP A 506 (-3.3A);ADP A 506 (-2.4A);None;ADP A 506 ( 4.6A);None","0.97A","3og7A-4ysjA:25.5","3og7A-4ysjA:22.11"],["3OG7_A_032A1_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",5,"VAL A 492;ALA A 512;LYS A 514;PHE A 642;GLY A 643","38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 ( 3.1A);EDO A1766 (-3.7A);EDO A1766 (-3.6A)","0.70A","3og7A-5a46A:27.0","3og7A-5a46A:27.92"],["3OG7_A_032A1_1","5d7a","Homo sapiens","TRAF2 AND NCK-INTERACTING PROTEIN KINASE","PF00069(Pkinase)",5,"VAL A  39;ALA A  52;LYS A  54;LEU A  73;PHE A 172","VAL A  39 (-0.6A);ALA A  52 (-0.0A);LYS A  54 ( 0.0A);LEU A  73 ( 0.6A);PHE A 172 ( 1.3A)","0.67A","3og7A-5d7aA:25.5","3og7A-5d7aA:29.41"],["3OG7_A_032A1_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",6,"VAL A 258;ALA A 275;LYS A 277;LEU A 305;THR A 325;PHE A 398","STU A 601 (-4.0A);STU A 601 (-3.1A);STU A 601 (-2.4A);STU A 601 ( 3.8A);STU A 601 ( 3.7A);None","0.81A","3og7A-5e8yA:25.0","3og7A-5e8yA:27.84"],["3OG7_A_032A1_1","5fd2","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE B-RAF","PF07714(Pkinase_Tyr)",12,"ILE A 463;VAL A 471;ALA A 481;LYS A 483;LEU A 505;LEU A 514;THR A 529;TRP A 531;CYH A 532;PHE A 583;PHE A 595;GLY A 596","5XJ A 801 ( 4.7A);5XJ A 801 (-4.6A);5XJ A 801 (-3.1A);5XJ A 801 (-3.8A);5XJ A 801 (-3.8A);5XJ A 801 (-4.5A);5XJ A 801 (-3.4A);5XJ A 801 (-4.4A);5XJ A 801 (-4.6A);5XJ A 801 (-4.3A);5XJ A 801 (-3.7A);5XJ A 801 (-3.7A)","0.57A","3og7A-5fd2A:37.3","3og7A-5fd2A:90.48"],["3OG7_A_032A1_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",5,"VAL A 607;ALA A 625;LYS A 627;THR A 674;CYH A 677","748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 (-3.2A);748 A1001 (-4.5A)","0.38A","3og7A-5grnA:26.9","3og7A-5grnA:28.07"],["3OG7_A_032A1_1","5hes","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","PF07714(Pkinase_Tyr)",7,"VAL A  30;ALA A  43;LYS A  45;LEU A  57;THR A  82;PHE A 152;GLY A 153","032 A 401 (-4.4A);032 A 401 (-3.2A);032 A 401 (-4.4A);032 A 401 ( 4.7A);032 A 401 (-3.7A);032 A 401 (-4.1A);032 A 401 (-3.6A)","0.60A","3og7A-5hesA:26.8","3og7A-5hesA:31.01"],["3OG7_A_032A1_1","5hor","Homo sapiens","HEPATOCYTE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"VAL A1092;ALA A1108;LEU A1140;PHE A1223;GLY A1224","63K A1401 (-4.9A);63K A1401 (-3.5A);None;None;None","0.54A","3og7A-5horA:26.0","3og7A-5horA:29.75"],["3OG7_A_032A1_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",5,"VAL A  30;ALA A  43;LYS A  45;CYH A  93;PHE A 155","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);6G2 A 901 ( 3.9A);TPO A 145 (-4.1A);None","0.74A","3og7A-5j5tA:22.1","3og7A-5j5tA:25.19"],["3OG7_A_032A1_1","5kkr","Homo sapiens","KINASE SUPPRESSOR OF RAS 2","PF07714(Pkinase_Tyr)",6,"ILE B 672;VAL B 680;ALA B 690;THR B 739;CYH B 742;PHE B 804","6U7 B1001 ( 4.8A);6U7 B1001 ( 4.3A);6U7 B1001 (-3.6A);6U7 B1001 (-4.0A);6U7 B1001 (-3.5A);6U7 B1001 (-3.8A)","1.01A","3og7A-5kkrB:17.0","3og7A-5kkrB:36.31"],["3OG7_A_032A1_1","5kkr","Homo sapiens","KINASE SUPPRESSOR OF RAS 2","PF07714(Pkinase_Tyr)",5,"ILE B 672;VAL B 680;ALA B 690;THR B 739;PHE B 793","6U7 B1001 ( 4.8A);6U7 B1001 ( 4.3A);6U7 B1001 (-3.6A);6U7 B1001 (-4.0A);6U7 B1001 (-4.3A)","0.71A","3og7A-5kkrB:17.0","3og7A-5kkrB:36.31"],["3OG7_A_032A1_1","5ko1","Homo sapiens","MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN","PF07714(Pkinase_Tyr)",5,"ALA A 228;LYS A 230;LEU A 263;CYH A 286;PHE A 350","6UY A 501 (-3.4A);6UY A 501 (-4.0A);None;6UY A 501 (-4.3A);None","0.79A","3og7A-5ko1A:26.1","3og7A-5ko1A:26.51"],["3OG7_A_032A1_1","5l6o","Homo sapiens","EPHRIN TYPE-B RECEPTOR 3","PF07714(Pkinase_Tyr)",5,"ILE A 639;VAL A 647;ALA A 663;LYS A 665;THR A 711","6P6 A1001 (-4.0A);None;6P6 A1001 (-3.3A);None;6P6 A1001 (-3.5A)","0.74A","3og7A-5l6oA:26.8","3og7A-5l6oA:30.38"],["3OG7_A_032A1_1","5o2c","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE WNK3","PF00069(Pkinase);PF12202(OSR1_C)",5,"VAL A 161;ALA A 174;LEU A 198;THR A 227;PHE A 282","None;GOL A 604 ( 3.8A);None;GOL A 604 (-3.9A);GOL A 604 ( 4.5A)","0.73A","3og7A-5o2cA:26.3","3og7A-5o2cA:26.04"],["3OG7_A_032A1_1","5tvt","Homo sapiens","MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE","no annotation",5,"VAL A  25;ALA A  38;LYS A  40;CYH A  89;PHE A 151","7LV A 401 ( 4.6A);7LV A 401 (-3.4A);7LV A 401 (-3.0A);7LV A 401 (-4.3A);None","0.79A","3og7A-5tvtA:23.3","3og7A-5tvtA:26.59"],["3OG7_A_032A1_1","5vcx","Homo sapiens","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","PF00069(Pkinase)",6,"VAL A 124;ALA A 137;LYS A 139;THR A 187;CYH A 190;GLY A 253","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-4.9A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None","1.13A","3og7A-5vcxA:18.1","3og7A-5vcxA:25.72"],["3OG7_A_032A1_1","5vcx","Homo sapiens","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","PF00069(Pkinase)",6,"VAL A 124;ALA A 137;THR A 187;CYH A 190;PHE A 240;GLY A 253","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 (-4.3A);None","0.67A","3og7A-5vcxA:18.1","3og7A-5vcxA:25.72"],["3OG7_A_032A1_1","5vcx","Homo sapiens","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","PF00069(Pkinase)",6,"VAL A 124;ALA A 137;THR A 187;CYH A 190;PHE A 240;PHE A 252","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);H8H A 401 (-4.3A);None","0.83A","3og7A-5vcxA:18.1","3og7A-5vcxA:25.72"],["3OG7_A_032A1_1","5vdk","Homo sapiens","WEE1-LIKE PROTEIN KINASE 2","PF00069(Pkinase)",5,"ILE A 218;VAL A 226;CYH A 292;PHE A 346;GLY A 382","8X7 A 501 ( 4.0A);8X7 A 501 ( 4.5A);8X7 A 501 (-3.8A);8X7 A 501 (-3.7A);None","0.78A","3og7A-5vdkA:22.7","3og7A-5vdkA:28.00"],["3OG7_A_032A1_1","5vo1","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 12","PF07714(Pkinase_Tyr)",5,"VAL A 139;ALA A 150;LYS A 152;CYH A 193;PHE A 255","9FS A 501 (-4.5A);9FS A 501 (-3.4A);None;9FS A 501 (-4.3A);None","0.74A","3og7A-5vo1A:27.3","3og7A-5vo1A:37.03"],["3OG7_A_032A1_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",5,"VAL A  32;ALA A  45;LYS A  47;LEU A  79;THR A  95","9WS A 401 ( 4.6A);9WS A 401 (-3.3A);9WS A 401 (-3.3A);9WS A 401 (-4.9A);9WS A 401 (-3.2A)","0.57A","3og7A-5w5jA:26.7","3og7A-5w5jA:29.21"],["3OG7_A_032A1_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",5,"VAL A 899;ALA A 917;LEU A 947;THR A 963;PHE A1029","ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-4.7A);ANP A1201 (-3.9A);None","0.54A","3og7A-5wnoA:27.3","3og7A-5wnoA:11.00"],["3OG7_A_032A1_1","5x1t","Serratia sp. FS14","PPKA-294","no annotation",6,"ILE A  29;VAL A  37;ALA A  50;LYS A  52;LEU A  93;THR A 118","None;ADP A 401 ( 4.5A);ADP A 401 (-3.4A);None;None;ADP A 401 (-4.1A)","1.04A","3og7A-5x1tA:21.8","3og7A-5x1tA:14.59"],["3OG7_A_032A1_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",5,"VAL A  41;ALA A  54;CYH A 102;PHE A 165;GLY A 166","ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-4.2A);None;None","0.69A","3og7A-6ao5A:24.5","3og7A-6ao5A:24.62"],["3OG7_A_032A1_1","6b4w","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE TTK","no annotation",5,"ILE A 531;VAL A 539;ALA A 551;LYS A 553;PHE A 665","CQ7 A 801 (-3.6A);CQ7 A 801 ( 4.8A);CQ7 A 801 (-3.2A);CQ7 A 801 (-3.2A);None","0.74A","3og7A-6b4wA:23.9","3og7A-6b4wA:28.75"],["3OG7_A_032A1_1","6bfn","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1","no annotation",6,"ILE A 218;VAL A 226;ALA A 237;LYS A 239;LEU A 263;PHE A 359","DL1 A 601 (-4.0A);None;DL1 A 601 (-3.4A);DL1 A 601 ( 4.1A);None;None","1.27A","3og7A-6bfnA:24.6","3og7A-6bfnA:13.75"],["3OG7_A_032A1_1","6cmj","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",6,"ILE A 171;VAL A 179;ALA A 192;LYS A 194;LEU A 240;PHE A 331","F6J A 501 (-4.3A);F6J A 501 (-4.6A);F6J A 501 (-3.4A);F6J A 501 (-2.9A);None;None","1.18A","3og7A-6cmjA:17.9","3og7A-6cmjA:16.49"]]